GPS Wealth Strategies Group LLC Sells 60 Shares of Cencora, Inc. (NYSE:COR)

GPS Wealth Strategies Group LLC decreased its stake in shares of Cencora, Inc. (NYSE:COR) by 9.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 590 shares of the company’s stock after selling 60 shares during the period. GPS Wealth Strategies Group LLC’s holdings in Cencora were worth $133,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Concord Wealth Partners bought a new position in shares of Cencora in the 3rd quarter worth approximately $30,000. Householder Group Estate & Retirement Specialist LLC raised its holdings in Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock worth $33,000 after purchasing an additional 69 shares in the last quarter. Ashton Thomas Securities LLC purchased a new position in Cencora during the third quarter valued at $41,000. Modus Advisors LLC bought a new stake in shares of Cencora during the 4th quarter valued at $54,000. Finally, Carolina Wealth Advisors LLC grew its position in shares of Cencora by 366.7% in the 3rd quarter. Carolina Wealth Advisors LLC now owns 266 shares of the company’s stock worth $60,000 after buying an additional 209 shares during the period. 97.52% of the stock is owned by institutional investors.

Insider Activity

In other news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the transaction, the chairman now owns 306,752 shares in the company, valued at $74,283,064.32. This represents a 6.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 73,187 shares of company stock valued at $17,790,912 in the last ninety days. 10.80% of the stock is currently owned by company insiders.

Cencora Stock Up 0.1 %

Shares of Cencora stock opened at $254.57 on Tuesday. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $261.25. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The company’s 50 day moving average is $238.74 and its 200 day moving average is $235.97. The company has a market cap of $49.20 billion, a price-to-earnings ratio of 33.90, a price-to-earnings-growth ratio of 1.59 and a beta of 0.49.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Mizuho initiated coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective on the stock. Evercore ISI boosted their price target on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. UBS Group raised their price objective on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Barclays increased their target price on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Finally, Wells Fargo & Company upped their price target on shares of Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 29th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $278.40.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.